Moreover, in investigations related to non-alcoholic steatohepatitis (NASH)—a condition that can promote liver cancer—researchers found that the inhibition of NET formation, either through treatment with deoxyribonuclease (DNase) or using peptidyl arginine deaminase type IV knockout mice (PAD4–/–), did not inhibit the development of fatty liver but altered the pattern of liver inflammation, ultimately resulting in reduced tumor growth [35]. The gene discussed is PADI4; the disease is metabolic dysfunction-associated steatohepatitis.